Brought to you by 
Celltech acquires Cistron for $18mm in stock, plus earnout
13 Apr 2000
Executive Summary
Celltech Group PLC will acquire Cistron (antibody and cytokine-based therapeutics and diagnostics) in exchange for $18mm in Celltech American depository shares--priced at the 5-day trailing average--paying $8.75mm for the company's intellectual property portfolio and $9.25mm for its cash reserves.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celltech acquires Cistron for $18mm in stock, plus earnout
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice